Key result
Tirzepatide improves HFpEF outcomes across body mass index categories and baseline adiposity levels.
Answers are grounded in this paper and cite their sources.
Observational analysis reveals significant links between BMI, central adiposity, and weight loss in HFpEF, suggesting targeted treatments may enhance outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Borlaug et al. (2025) studied this question. Tirzepatide's benefits in heart failure with preserved ejection fraction were evaluated for their relationship with body mass index, central adiposity, and weight loss.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: